Successful Ombitasvir/Paritaprevir/Ritonavir Plus Ribavirin Retreatment for a Chronic Hepatitis C Genotype 2a Patient Who Relapsed after Sofosbuvir Plus Ribavirin Treatment

The optimum retreatment strategy for chronic hepatitis C virus (HCV) patients who failed directly-acting antiviral agents (DAA)-based therapy is unknown. We herein report the outcomes of an HCV genotype (GT) 2a-infected patient with virologic failure following treatment with sofosbuvir plus ribaviri...

Descripción completa

Detalles Bibliográficos
Autores principales: Ishikawa, Toru, Imai, Michitaka, Owaki, Takashi, Sato, Hiroki, Nozawa, Yujiro, Sano, Tomoe, Iwanaga, Akito, Seki, Keiichi, Honma, Terasu, Yoshida, Toshiaki
Formato: Online Artículo Texto
Lenguaje:English
Publicado: The Japanese Society of Internal Medicine 2018
Materias:
Case Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6207807/
https://www.ncbi.nlm.nih.gov/pubmed/29780129
http://dx.doi.org/10.2169/internalmedicine.0621-17

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6207807/
https://www.ncbi.nlm.nih.gov/pubmed/29780129
http://dx.doi.org/10.2169/internalmedicine.0621-17

Ejemplares similares